Protocol Ledger

NCT04935177 · Phase III · COMPLETED

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

Interventional Phase III clinical trial protocol NCT04935177 sponsored by Hansa Biopharma in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-14 Enrollment: 64 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04935177
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)64 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04935177
Protocol FieldVerified Registry Value
NCT IdentifierNCT04935177
Consolidated Lead SponsorHansa Biopharma
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment64 participants (ACTUAL)
Registered Start Date2021-10-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI